London, UK, 5 May 2021

Trackwise Designs (TWD): Agreement in medical devices market

Trackwise has announced a seven-year supply agreement with CathPrint, which has created a novel technique for manufacturing catheters. Assuming the ongoing development project supplying Trackwise's Improved Harness Technology (IHT) to CathPrint for advanced catheters is successful, this potentially represents sales of significant volumes of IHT for medical applications from FY23 onwards. This announcement coincides with the news that Trackwise has completed the acquisition of a new site in Gloucestershire, UK. The site will provide additional capacity to support potential volume programmes in the medical sector as well as the previously announced order worth up to £38m over three years from a UK electric vehicle (EV) OEM.

In line with its expansion strategy outlined in November 2020, Trackwise has completed the acquisition of a new 77,000 sq ft freehold property in Gloucestershire for £2.8m. Trackwise will install an automated roll-to-roll IHT production line at the site, which management expects will commence operation in Q421. Expansion into this site is critical to meet the production requirements for the EV OEM. The site will also be able to support volume production for the medical device market in future years.

to view the full report

All reports published by Edison are available to download free of charge from its website

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Anne Margaret Crow +44 (0)20 3077 5700

Learn more at and connect with Edison on: 

LinkedIn       

Twitter          

YouTube